Poseida Therapeutics Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Kristin Yarema
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 14.7% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.6yrs |
Recent management updates
Recent updates
Poseida Therapeutics: What The Acquisition Offer Says About Big Pharma Priorities
Nov 26Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%
Oct 19
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement
Sep 30Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024
Sep 09Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop
Aug 28Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
May 21Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%
Apr 09Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement
Mar 17Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?
Jan 24Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)
Aug 13Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding
Apr 17Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech
Sep 04Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M
Aug 11Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B
Aug 03Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25
May 15Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
Oct 30What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?
Mar 19CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$61m |
| Jun 30 2024 | n/a | n/a | -US$113m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$3m | US$381k | -US$123m |
Compensation vs Market: Kristin's total compensation ($USD2.58M) is about average for companies of similar size in the US market ($USD3.24M).
Compensation vs Earnings: Insufficient data to compare Kristin's compensation with company performance.
CEO
Kristin Yarema (53 yo)
less than a year
Tenure
US$2,581,106
Compensation
Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | US$3.82m | 0.15% $ 1.4m | |
| President | less than a year | US$2.58m | no data | |
| Chief Financial Officer | 4.4yrs | no data | 0.073% $ 670.6k | |
| Chief Operations Officer | 2.9yrs | no data | no data | |
| Chief People & Administration Officer | 5.9yrs | no data | no data | |
| Senior VP of Investor Relations & Corporate Communications | less than a year | no data | no data | |
| General Counsel | 4.4yrs | US$978.34k | 0.040% $ 371.6k | |
| Chief Scientific Officer of Cell Therapy | 4.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 3.2yrs | no data | no data | |
| Senior VP & Chief Patent Counsel | 2.9yrs | no data | no data | |
| Senior Vice President of Business Development | 2.9yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
2.9yrs
Average Tenure
57yo
Average Age
Experienced Management: PSTX's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.9yrs | US$3.82m | 0.15% $ 1.4m | |
| President | less than a year | US$2.58m | no data | |
| Lead Independent Director | 6.4yrs | US$175.11k | 0.040% $ 371.4k | |
| Chairman of Cell Therapy Scientific Advisory Board | 3.8yrs | no data | no data | |
| Chairman of Gene Therapy Scientific Advisory Board | 2.4yrs | no data | no data | |
| Independent Director | 5.9yrs | US$149.11k | 0.051% $ 465.9k | |
| Independent Director | 3.4yrs | US$155.28k | 0.040% $ 371.4k | |
| Independent Director | 2.6yrs | US$150.28k | 0.047% $ 433.3k | |
| Independent Director | 4yrs | US$140.11k | 0.040% $ 371.4k | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.6yrs | no data | no data |
3.6yrs
Average Tenure
66yo
Average Age
Experienced Board: PSTX's board of directors are considered experienced (3.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:57 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Poseida Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Justin Zelin | BTIG |
| Jennifer Kim | Cantor Fitzgerald & Co. |